Many investors will be carefully reviewing company earnings results when they are released to the public. They will most likely be keeping a close eye on how the actual results stack up to Wall Street analyst estimates. According to analysts polled by Zacks Research, the current quarter EPS consensus estimate is resting at -1.26 for shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC). The number consists of projections offered by 4 contributing analysts. For the last quarter, the company posted a quarterly EPS of -1.19.
Diversification can be an important aspect of any investor’s portfolio. Investors may choose to spread out stock holdings between foreign stocks and stocks with different market capitalizations. Investors may have to first become aware of the risk associated with owning a wide variety of stocks. Owning stocks that belong to different industries may also be a help to the success of the portfolio. Often times, sectors may trade off being market leaders. Owning all one sector may leave too much risk exposed if the sector suddenly tanks and falls out of favor with investors. Investors may need to occasionally do a strategic review of the equity portion of the portfolio. Knowing exactly what is held may help the investor when the time comes to make some adjustments.
Shifting the focus to some possible support and resistance levels on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC), we note that the 52-week high is currently $38.44, and the 52-week low is currently $16.89. When shares are trading near to the 52-week high or 52-week low, investors may be watching for a break through either level. Investors may also be watching historical price action. Over the past 12 weeks, the stock has moved -8.44%. Going back to the start of the year, we can see that shares have moved 79.41%. Over the last 4 weeks, shares have seen a change of -8.55%. Over the last 5 trading days, the stock has moved 29.48%. Checking in on recent session activity, we have seen that the stock has been trading near the $31.45 mark.
Looking further at shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC), we have noticed that the current consensus target price is $52. Wall Street analysts have the ability to create price target estimates for where they think the stock will be moving in the near-term. Because price target projections can differ from one analyst to the next, they may span a wide range of values. Many investors will closely track target prices, and they tend to pay extra close attention when analysts make revisions to those targets.
Wall Street analysts often give buy/sell/hold ratings for the companies that they track. Investors have the ability to view these sell-side ratings in order to help with their own stock research. Analyst ratings may have different interpretations. According to analysts polled by Zacks Research, the current average broker rating on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is 1.57. This rating uses a scale between 1 and 5. Following this scale, a rating of 1 would represent a Strong Buy, and a rating of 5 would indicate a Strong Sell recommendation. Out of all these analysts offering ratings, 6 have rated the stock a Strong Buy or Buy, according to Zacks Research.